Prognostic nomogram for overall survival in upper urinary tract urothelial carcinoma (UTUC) patients treated with chemotherapy: a SEER-based retrospective cohort study

被引:0
作者
Cong Tian
Jun Liu
Lizhe An
Yang Hong
Qingquan Xu
机构
[1] Peking University People’s Hospital,Department of Urology
[2] Peking University,Peking University Applied Lithotripsy Institute
来源
BMC Urology | / 23卷
关键词
SEER; Nomogram; Prognosis; Upper urinary tract urothelial carcinoma; Chemotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 202 条
[1]  
Siegel RL(2022)Cancer statistics, 2022 CA A Cancer J Clin 72 7-33
[2]  
Miller KD(2011)Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005 BJU Int 107 1059-1064
[3]  
Fuchs HE(2017)Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC) World J Urol 35 379-387
[4]  
Jemal A(2011)Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma World J Urol 29 481-486
[5]  
Raman JD(2020)Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract J Surg Oncol 121 1154-1161
[6]  
Messer J(2021)Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy Eur Urol 79 635-654
[7]  
Sielatycki JA(2019)High response rates to neoadjuvant chemotherapy in high-grade upper tract urothelial carcinoma Urology 129 146-152
[8]  
Hollenbeak CS(2020)Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial Lancet (London, England) 395 1268-1277
[9]  
Soria F(2018)Revisiting the prognostic heterogeneity of AJCC stage IV carcinomas of the upper urinary tract Clin Genitourin Cancer 16 e859-e865
[10]  
Shariat SF(2017)Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review World J Urol 35 337-353